Alaunos Therapeutics (TCRT) Non-Current Debt (2016 - 2022)

Alaunos Therapeutics (TCRT) reported Non-Current Debt of $4.5 million for Q2 2022, down 56.68% quarter-over-quarter from $10.3 million in Q1 2022.

Alaunos Therapeutics (TCRT) Non-Current Debt (2016 - 2022) Analysis & Trends

Alaunos Therapeutics has reported Non-Current Debt for 3 years, with the latest figure at $4.5 million in Q2 2022.

For the quarter ending Q2 2022, Non-Current Debt changed N/A year-over-year to $4.5 million; the trailing twelve-month figure through Jun 2022 stood at $4.5 million (changed N/A YoY), and the FY2021 full-year result was $16.2 million, changed N/A from the prior year.
Non-Current Debt for Q2 2022 stood at $4.5 million, down from $10.3 million in the prior quarter.
The five-year high for Non-Current Debt was $16.2 million in Q4 2021, with the low at $4.5 million in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	319.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Alaunos Therapeutics	4.31 Mn	3.95 Mn	-	-

Download Data